Kura Oncology, Inc. — Fiscal 2017 Form 10-K Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology medicines and associated molecular diagnostics. The filing covers the fiscal year ended December 31, 2017; it is an annual report rather than a standalone fourth-quarter filing.
- Lead program: tipifarnib, an oral farnesyl transferase inhibitor, primarily being evaluated in HRAS-mutant head and neck squamous cell carcinoma (HNSCC) and selected hematologic malignancies.
- Other programs: KO-947, an ERK inhibitor in Phase 1, and KO-539, a menin-MLL inhibitor in preclinical development.
- The company had 31 full-time and one part-time employee at December 31, 2017, and had no approved products or product sales.
Financial performance, liquidity and capital structure
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue from product sales | None | None | Not applicable |
| Net loss | $35.4 million | $27.6 million | Loss increased $7.9 million |
| Net loss per share, basic and diluted | $1.52 | $1.47 | Loss per share increased |
| Research and development expense | $26.4 million | $20.4 million | Increased $6.0 million |
| General and administrative expense | $9.7 million | $8.0 million | Increased $1.7 million |
| Other income, net | $0.6 million | $0.8 million | Decreased $0.2 million |
| Net cash used in operating activities | $28.4 million | $25.3 million | Use increased $3.1 million |
| Net cash provided by financing activities | $53.6 million | $7.5 million | Increased $46.1 million |
- Cash and cash equivalents were $11.4 million and short-term investments were $81.7 million at year-end, for total cash, cash equivalents and short-term investments of $93.1 million.
- Accumulated deficit was $89.3 million.
- Total assets were $95.9 million; total liabilities were $16.0 million; and stockholders’ equity was $79.9 million.
- Long-term debt had a principal balance of $7.5 million and a net carrying value of $7.1 million, including $1.5 million classified as current. The loan bears interest at a variable rate; the rate was 8.75% at December 31, 2017, and matures November 1, 2020.
- The term loan is secured by substantially all assets other than intellectual property and contains restrictive covenants. The company reported compliance with the covenants at year-end.
- Share-based compensation expense increased to $4.5 million from $2.1 million.
- The company reported no off-balance-sheet arrangements and no material legal proceedings.
Material changes versus the prior comparable period
- Research and development expense increased 30%, primarily because of higher tipifarnib clinical development, companion-diagnostic, manufacturing and internal personnel costs.
- External tipifarnib spending increased to $12.9 million from $6.3 million, while spending on discovery and preclinical programs declined to $2.2 million from $5.7 million.
- Operating cash use increased as the company expanded development activities and incurred higher net losses.
- Investing activities shifted from $12.2 million of net cash provided in 2016 to $23.4 million of net cash used in 2017, primarily reflecting increased purchases of marketable securities.
- In August 2017, the company sold 8.805 million shares in a public offering for approximately $53.5 million of net proceeds.
- The additional $12.5 million draw under the term-loan facility expired unused in October 2017; the company paid an unused fee of approximately $0.3 million.
- In January 2018, after year-end, the company sold 3.137 million shares through its ATM facility for gross proceeds of approximately $59.1 million. As of March 9, 2018, cumulative ATM gross proceeds were approximately $59.3 million.
Clinical progress, guidance, outlook and risks
- The ongoing Phase 2 tipifarnib trial in HRAS-mutant HNSCC met its primary efficacy endpoint before enrollment was complete: four confirmed partial responses were observed among the first six evaluable patients as reported in September 2017. Updated February 2018 data showed five confirmed partial responses among six evaluable patients, with two responses lasting more than 18 months.
- The company planned to initiate the potentially registration-enabling AIM-HN Phase 2 trial in the second half of 2018. The proposed global, single-arm trial was expected to enroll at least 59 patients, with objective response rate assessed by independent radiological review.
- The FDA indicated that the proposed AIM-HN design might support an accelerated-approval NDA if successful, but approval was not assured and would be revisited at a pre-NDA meeting.
- Management expected additional hematologic-malignancy data in the second half of 2018 and targeted proof-of-concept in at least one indication by year-end 2018.
- KO-947 Phase 1 data were expected in the second half of 2018. An IND submission for KO-539 was anticipated in late 2018 or early 2019, subject to successful IND-enabling studies.
- Management stated that year-end cash, cash equivalents and short-term investments were expected to fund current operations into the first half of 2020. The filing also states that additional financing will be required and that no committed external source of funds exists.
- Key risks include failure to replicate early tipifarnib results in AIM-HN, small and difficult-to-identify biomarker-defined patient populations, slow enrollment, adverse clinical outcomes, regulatory delay or non-approval, and the need for an approved companion diagnostic for HRAS-mutant HNSCC.
- Tipifarnib’s composition-of-matter patents expired in the United States and Europe in 2016. The company relies on method-of-use patents, regulatory exclusivity and other intellectual-property protections that may be challenged or prove insufficient.
- The company relies on third parties for clinical research, manufacturing and companion-diagnostic development, creating execution, supply, quality and regulatory risks.
- Future equity or debt financing could dilute existing stockholders or impose restrictive terms. The company does not expect to pay dividends.
Important facts for investors to verify
- Whether the AIM-HN trial began on schedule, its final protocol and enrollment pace, and whether independent radiological review confirms the earlier investigator-assessed responses.
- Updated efficacy, durability and safety data for tipifarnib in HRAS-mutant HNSCC and hematologic malignancies.
- Availability and regulatory progress of the required HRAS companion diagnostic.
- Actual quarterly cash burn, remaining cash runway and the timing and terms of future financing.
- Debt repayment requirements beginning June 2018, covenant compliance and collateral restrictions.
- Progress and safety findings for KO-947 and the timing of the KO-539 IND submission.
- Patent validity, remaining exclusivity and royalty or milestone obligations under the Janssen, Araxes and University of Michigan agreements.